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www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMMethods: Of 380 patients from Europe registered in the MFM Global Registry after
treatment for thoracoabdominal aortic aneurysm (TAAA) or dissection, 38 (10%)
patients (30 men; median age 71 years, range 30–91) treated a compassionate basis
outside the IFU were analyzed. Thirteen patients had chronic Stanford type B
dissection with aneurysmal dilatation >6 cm. There were 6 mycotic and 4 saccular
aneurysms in addition to 15 primary TAAAs. The mean aneurysm diameter was 7.1
cm. Ten patients presented with rupture, and 23 patients had previous open or thoracic
endovascular aortic repair (TEVAR).
Results: Although no death, paraplegia, stroke, or renovisceral compromise was docu-
mented during the initial hospital stay, technical success was zero. There were 31 cases
(81.6%) inwhich therewas failure to land thedevice innormal aorta.Other violations of the
IFU included 12with inadequate stent overlap and 11 cases involving a smallMFMbeing
deployed inside a larger one. Overall survival, freedom from aneurysm-related death, and
rupture-free survival estimates were 17.5%, 25.0%, 31.5%, respectively, at 18 months.
There were 8 visceral branch complications; in all, 14 secondary endovascular in-
terventions were required in 11 patients for endoleak or stent foreshortening. No false
lumen was completely thrombosed in the dissecting aneurysms. All aneurysms showed a
mean sac growth rate of 0.120.16 cm/month. Factors having a signiﬁcance inﬂuence on
risk of aneurysm-related death included aneurysm diameter (p¼0.025), previous TEVAR
(p¼0.03), and inadequate overlap between devices (p< 0.002).
Conclusions: There are clinical scenarios in which the MFM does not perform well.
MFM is not a solution for patients living on borrowed time and should not be used
indiscriminately in patients in whom other modalities of aortic repair are not feasible.
It use must adhere to the IFU, and robust clinical data are required before constructing
a randomized controlled trial.
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Background: Type-II endoleak(T-II) after endovascular abdominal aneurysm
repair(EVAR) is an unresolved phenomenon. We aimed to investigate the impact of
T-II on aneurysm sac growth and reveal preoperative T-II predictors.
Methods:Weenrolled162consecutivepatients(Zenith:61,EXCLUDER:57,ENDURANT:44)
who underwent successful EVAR without Type-I or Type-III endoleak and had at least
1-year follow-up. Computed tomography(CT) before and after EVAR(1week, 6month, and
1year) were reviewed to estimate T-II and measure sac diameter. Three-dimensional vol-
ume analyses were performed during CT for measuring sac volume. Vessel number and
diameter of the patent lumbar artery(LA) and inferior mesenteric artery(IMA) were eval-
uated. Variable anatomical parameters and patient characteristics were investigated as
possible T-II predictors.
Results: T-II was 35.8%, 15.4%, and 12.3% at 1week, 6months, and 1year after EVAR,
respectively. The mean preoperative maximum sac diameter and volume were
50.18.2mm and 153.875.5ml, respectively, without differences between T-II
cases(T-II-group) and absence of T-II cases(non-T-II-groups). Signiﬁcant differences in
the reduction of sac diameter(T-II-group:-0.113.4mmvs non-T-II-group:-7.36.0mm
p< 0.0001) and volume(T-II-group:-0.0714.6ml vs non-T-II-group:-24.230.7ml
p¼0.0007) was observed between two groups at the 1year after EVAR. Sac growth
was observed in 47.6% cases in the T-II-group. EXCLUDER use, patent LA, patent
IMA, and IMA diameter were signiﬁcantly associated to T-II- at 1week after EVAR
in univariate analysis. Dual antiplatelet therapy(DAPT), EXCLUDER use, number of
LA and patent IMA were signiﬁcantly associated to T-II at 1year after EVAR. Multi-
variate analysis revealed that DAPT and EXCLUDER use were independent predictors
of T-II at 1year after EVAR. Patent IMA was the only signiﬁcant correlative factor of
sac growth in patients with persistent T-II.
Conclusions: Persistent T-II after EVAR was observed in 12% cases. DAPT and
EXCLUDER use were independent predictors of persistent T-II. Sac growth was
observed in half of the patients with persistent T-II. Because T-II with patent IMA was
signiﬁcantly associated with sac growth, careful observation or additiona.
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Background: Percutaneous treatment of aortic coarctation (AC) is usually guided
with intravascular contrast injections and hemodynamic parameters. Intravascular
ultrasound (IVUS) guidance might be useful to choose adequate balloons and stents
sizes and to optimize the ﬁnal result after angioplasty, but there are few reports in the
literature.
Methods: Eleven patients (91% male), mean age 2418 years (range 7-63), with a
diagnosis of native AC (36%) or recoarctation (64%) conﬁrmed with non-invasive
imaging techniques (echocardiography and magnetic resonance or computerized to-
mography), were included. Simultaneous radial and femoral access was used in all cases.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/AoAfter standard aortography in 2 projections (lateral and anteroposterior), the anatomy of
the aorta was studiedwith IVUS (Ultra ICE 9F 9MHz, Boston Scientiﬁc) from the arch
down to the diaphragm, and again after the angioplasty was performed.
Results: The procedure was successful in all cases. Mean gradient changed from
339 mmHg (baseline) to 45 mmHg (ﬁnal). Minimal lumen diameter of the AC
with angiography was 8.12.2 mm and with IVUS 9.41.9 mm (p< 0.05). Stents
were implanted in 10 patients (91%), in seven cases covered stents were used and bare
metal stents in the rest. One patient was treated only with high pressure inﬂation of a
non-compliant balloon inside a previously implanted stent. Mean diameter of the
balloons where the stent was mounted was 15.62.9 mm (12-22), mean length of the
stent was 35.55.3 mm (28-45), and mean diameter of postdilatation balloons was
174.2 mm (12-25). Intrastent postdilatation was performed in 73% of cases, mainly
due to signiﬁcant stent infraexpansion detected with IVUS. All patients were dis-
charged in 24-48 hours without signiﬁcant complications. The use of IVUS changed
the initial strategy, based only in angiography, in 73% of cases (balloon size, stent
length or need for postdilatation).
Conclusions: IVUS guidance during percutaneous treatment of AC modiﬁes in a high
percentage of cases the treatment strategy based only in angiography. There are sig-
niﬁcant anatomic differences between angiographic and IVUS measures.
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Background: Thoraco Abdominal Aortic Aneurysms (TAAA) and Abdominal Aortic
Aneurysms (AAA) are traditionally treated surgically, but more and more by inter-
ventional procedures (endografts, fenestrated, branched grafts, chimney techniques).
We used a new concept of stent, the Multilayer Stent Flow Modulator (M.F.M) to treat
these aneurysms (A) and try to avoid some major complications.
Methods: This selfexpandable M.F.M is a 3 D braided tube made of several inter-
connected layers without any covering. We will explain and demonstrate the key
principles of the stent leading to thrombosis, shrinkage of the A, eliminating the risk of
rupture. Moreover, this M.F.M preserves the collateral branches allowing the possi-
bility to cover any artery without compromising the ﬂow (renal, digestive arteries,
supra aortic vessels.)
Results: 10 TAAA, 8 AAA (7 extended to both iliac arteries) treated with MFM in
very high risk patients. 53 MFM implanted (1 to 5 per pt). o Technical success: 100%
o At 30 days: no neurological complication, branch patency 100%, no death o During
the follow up we had 3 deaths not device related. CT scan control performed at 1, 3, 6,
12, 18 months with calculation of A. Diameters and Volumes. o All collateral
branches remain patent and we observed a progressive thrombosis and shrinkage of
the aneurysmal sac depending on the size of the collaterals. Some patients developped
a thrombus after 1 month, some after 6 months and some even after 18 months. o A
signiﬁcant mean diameter reduction was observed between baseline and 6 months:
17,25 mm reduction for the transversal diameter, 13,83 mm for the antero posterior
diameter in the TAAA group. o Overtime the ratio thrombus volume / Total Volume is
increasing and the ratio Residual Flow Volume / Total Volume is decreasing. The
problems of thrombosis, shrinkage and volume reduction of the aneurysmal sac will
be discussed. The complications rates with M.F.M appear lower in comparison with
current endovascular techniques, and with surgery.
Conclusions: The M.F.M represents an alternative to current devices to treat TAAA
and AAA. It is a safe procedure with a low complication rate. The ﬁrst results are
promising. A larger study is ongoing.
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Background: Aortic dissection during pregnancy is a morbid condition for both the
mother and her fetus. There is scant data on the incidence, risk factors, and outcomes
of aortic dissection during pregnancy.
Methods: The Nationwide Inpatient Sample (NIS) Database was queried for cases of
pregnancy and aortic dissection from 1998-2008. The primary analysis identiﬁed
speciﬁc medical co-morbidities increasing the risk of aortic dissection during
pregnancy.
Results: We identiﬁed 10,550,421 pregnant women and 41,088 aortic dissections in the
NIS Database from 1998-2008. From these cases, we identiﬁed 44 cases of aortic
dissection in pregnancy. The rate of aortic dissection in pregnancy was .0004%, and
represented only 0.1% of all cases of aortic dissection. Mean age of aortic dissection was
younger (31-years-old vs. 69-years-old). The incidenceofMarfan’s syndromewashigher
(15.9% vs. 1.8%, p< 0.00001) and the incidence of hypertension was lower (18.2% vs.
68.3%, p< 0.00001). 14 out of the 44 pregnant patients with aortic dissection underwent
operative repair of the aorta. Patient death was lower in cases of aortic dissection during
pregnancy compared to the general population (6.8% vs. 15.4%, p< 0.03).
Conclusions: Aortic dissection during pregnancy is an extremely rare event with a
signiﬁcantly higher incidence of Marfan’s Syndrome but lower incidence of mortality.rtic Endograft Intervention (not aortic stenosis) B165
